CASE REPORT article
Front. Med.
Sec. Pulmonary Medicine
Volume 12 - 2025 | doi: 10.3389/fmed.2025.1659090
This article is part of the Research TopicCase Reports in Pulmonary Medicine 2025View all 11 articles
The efficacy of low-dose Anlotinib as a first-line treatment for frail patients with lung adenocarcinoma and its bridging significance for subsequent treatment: case report
Provisionally accepted
- 1The People’s Hospital of Gaozhou, Gaozhou, China
- 2Guangdong Medical University, Zhanjiang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This case report describes a 49-year-old male patient with advanced lung adenocarcinoma (cT3N3M1b, stage IVA), brain metastases, an ECOG PS of 3, negative driver gene status and low PD-L1 expression (TPS 1%). Traditional treatment options were limited. Following a multidisciplinary team consultation, the patient was prescribed a low dose of anlotinib (8mg/day on d1-14, q21d) as a first-line treatment. Following two cycles of treatment, there was a significant improvement in symptoms (muscle strength recovery and the ability to walk independently), and an imaging assessment revealed shrinkage of the primary tumour and brain metastases. After seven cycles, the ECOG PS improved to 0, but after 11 cycles, progression occurred (tumour enlargement and new effusion). Switching to a combination of pemetrexed disodium and bevacizumab resulted in another response. The patient's overall survival reached 16 months (anlotinib PFS: nine months).This case suggests that low-dose anlotinib may serve as a bridging therapy for patients with advanced non-small cell lung cancer (NSCLC) and a poor general condition, improving their physical status and creating conditions for subsequent treatment. The potential of anlotinib for first-line application and strategies for overcoming drug resistance warrant further exploration.
Keywords: Non-small cell lung cancer, Anlotinib, Adenocarcinoma, First-line treatment, Low-dose therapy
Received: 03 Jul 2025; Accepted: 14 Aug 2025.
Copyright: © 2025 Huang, Wang and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jiawei Huang, The People’s Hospital of Gaozhou, Gaozhou, China
Bomeng Wu, The People’s Hospital of Gaozhou, Gaozhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.